alexa Ambovex Oral Sublingual Spray As Immuno-therapy Trial For HCC Among Egyptian Patients
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Cancer Science & Therapy
October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Hosny Salama
Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.035
Novel immunotherapy strategies are employed to render cancer more immunogenic, generate antigen-specific or nonspecific immune activation, and/or manipulate the tumor micro- environment. A number of immunotherapeutic trials have been tried for this purpose . Ambovex is a botanical medicine derived from the plants belonging to the family Ranunculaceae and have immune-modulating effect. In this pilot study we used Ambovex as an immunotherapy trial for treating Egyptian patients with un-resectable HCC. We included 148 patients with post-HCV liver cirrhosis and HCC unfit for any of the available treatment modalities. They were divided into 2 groups: Group 1 (88 patients) for treatment and group 2 (60 patients) as control . After their consent, group 1 received Ambovex sublingual oral spray (20 buffs tid) for 4 months. Group 2, received glucose-saline sublingual spray as placebo. Both groups were followed up for one year. In group I there was tumor regression and significant decrease in AFP in 40.9%, and 28.4% showed stable tumor size and AFP level , however 30.7% showed disease progression. In group II, no patients showed tumor stabilization. At one year follow-up , 69.3% were still living in group I compared to 35% in group II. From this study, we concluded that Ambovex with its immune- modulating effect have initial promising results in treating HCC. Further controlled, randomized, multicenter studies are needed to confirm these results.
Hosny Salama got experience in diagnosis and treatment of HCC through his work for 35 years at Hepatology Department, Cairo University. He was selected director for the Department on 1991. He supervised 63 MS and 28 MD thesis with 65 National and International publication. He published the first study done in Egypt using RF in HCC on 2003. He established the Egyptian Societies of Stem Cell Therapy and Study of NASH and its Complication and was selected as president.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version